Pharming's Leniolisib Shows Promise in Broader PID Population…

Event summary

Pharming presented positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026.
Leniolisib demonstrated improvements in spleen volume, lymph nodes, pulmonary function, and liver disease markers.
All 12 participants who completed the study enrolled in a three-year extension study.
The trial enrolled 13 participants with genetically identifiable PIDs driven by variants in CTLA4, SOCS1, NFKB1, or FAS genes.
Leniolisib was generally well-tolerated, with no new safety signals identified.

The big picture

Pharming's Phase II data for leniolisib in genetic PIDs with immune dysregulation marks a strategic pivot from its current focus on APDS. The results suggest potential for a broader patient population, aligning with industry trends toward targeted therapies for rare immune disorders. The company's ability to translate these findings into regulatory approvals and commercial success will be critical in a competitive biotech landscape.

What we're watching

Clinical Validation: Whether leniolisib's efficacy in broader PID populations can be sustained in larger, controlled trials.
Regulatory Pathway: The pace at which Pharming advances leniolisib for potential registration in CVID and other PIDs.
Market Expansion: How Pharming leverages these results to expand leniolisib's commercial potential beyond APDS.